Amneal Pharmaceuticals

The U.S. FDA has awarded Amneal more Competitive Generic Therapy (CGT) product approvals than any other company since the FDA created the approval pathway. CGT designation is given when there is inadequate generic competition on the market for a specific drug. https://lnkd.in/dzfSDqp9 (Accessed: November 19, 2025)

We received U.S. FDA approval for iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare’s Omnipaque® (iohexol) injection. We expect to launch the product in Q1 2026. Learn more: https://lnkd.in/eEtvStFV   This approval reinforces our growing leadership in differentiated, complex injectables and our ongoing commitment to improving access to high-quality, affordable medicines.   Note: OMNIPAQUE is a registered trademark of GE HealthCare or one of its subsidiaries

For us, medicine is personal. From affordable access to innovative therapies, we combine heart with precision to tackle tomorrow’s health challenges head on. We’re building a world where none of our loved ones — regardless of circumstances — struggle to obtain the treatments they need.

23 years ago, Amneal co-CEOs and founders Chirag and Chintu Patel witnessed firsthand the difficulty many patients face in affording their medicines. Believing there had to be a better way, they formed Amneal to help patients get the medicine they need. Learn more about our inspirational story: Amneal.com

This week, we recognize the 6th annual Global Biosimilars Week and the important progress biosimilars continue to make in expanding access and strengthening healthcare systems worldwide. With a portfolio of seven biosimilars — three commercialized and four in development — we’re proud to support the continued growth of this important area of medicine. Thank you to the IGBA - International Generic and Biosimilar medicines Association for leading this annual initiative and driving awareness of the value biosimilars bring to patients and providers. Learn more about our commitment to advancing biosimilars at amnealbiosciences.com #GlobalBiosimilarsWeek

We’re incredibly proud to be recognized by BioSpace as a 2026 Best Place to Work — ranking among the top five large employers in the life sciences industry! Our culture is grounded in our mission of Making Healthy Possible and built on integrity, collaboration, and shared ownership. This recognition reflects our people-first values and our collective commitment to creating a place where talented, passionate individuals can grow, thrive, and make a meaningful impact. Learn more: https://lnkd.in/e5su8_dc Learn more about BioSpace’s Best Places to Work: https://lnkd.in/gKuFq2cG

We’re focused on delivering innovative & affordable medicines that make a difference for patients and providers. Our strategic expansion from generics into specialty, biosimilars, injectables, GLP-1, and complex medicines is driving significant and sustainable top and bottom-line growth. It’s our team of 8,100 global employees that makes it all happen! For more information, please reference Amneal’s third quarter press release, including non-GAAP financial measures, reconciliations and risks related to forward-looking statements: https://lnkd.in/eitdUMHk

Colleagues from our Glasgow, Kentucky team recently walked in support of the Moving Day Parkinson’s Walk, in Nashville, Tennessee. Through partnerships with various advocacy organizations, we support meaningful programs and build important community connections.

Brekiya® (dihydroergotamine mesylate) injection, the first and only DHE autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headache in adults, is now available in the U.S. (1,2) See Warning: Do not take with strong CYP3A4 inhibitors due to the potential for serious or life-threatening interactions. See full Prescribing Information, including BOXED WARNING, and Medication Guide at http://Brekiya.com. The Brekiya® autoinjector is now available only by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy. Learn more: https://lnkd.in/ehpeXFyF References: 1. Brekiya package insert: https://lnkd.in/eysSQiNS . Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2025. 2. Data on File. Amneal Pharmaceuticals LLC. 

Over the past few weeks, our teams across the U.S. participated in our annual volunteering campaign, to pack essential hygiene kits with Heart to Heart International. These essential hygiene kits are being distributed to local communities. Supporting our neighbors in need is one way we make healthy possible.